Market Extra: Key question for stock investors: Take profits or sit tight in what could be a ‘make or break’ March
A February setback to the early 2023 stock-market rally leaves investors wondering whether to take profits or add to positions.
: Laid-off Meta cafeteria workers ask for the same severance as the company’s employees
The workers and their union supporters plan to rally at the company's headquarters in Menlo Park, Calif., on Wednesday afternoon.
The Margin: TikTok’s screen time limit for teens: How it works, and how to get around it
TikTok says it's promoting conversations about 'digital well-being' in its new 60-minute screen limit for teens
Cannabis Watch: Cannabis company Green Thumb beats revenue estimate but posts loss on noncash impairment
CEO Ben Kovler says the company grew its cash from the previous quarter but that 'nothing is a straight line' when it comes to state-by-state...
: Gold futures post a third straight session climb
Gold futures finished higher on Wednesday for a third consecutive session. Prices for the precious metal got a boost as the U.S. dollar weakened in...
: National Vision stock plunges toward record selloff on heavy volume after disappointing results and outlook, but one analyst says selloff is ‘overly harsh’
Shares of National Vision Holdings Inc. EYE plummeted 37.9% in very active afternoon trading Wednesday, putting them on track for a record one-day selloff and...
: Sarepta’s stock still up after Tuesday’s announcement that its Duchenne drug candidate won’t require a FDA AdCom meeting
Shares of Sarepta Therapeutics Inc. SRPT were up 18.7% in trading on Wednesday afternoon, a day after the company told investors that the Food and...
: U.S. oil futures mark highest finish in nearly 2 weeks
U.S. benchmark crude-oil prices on Wednesday settled at their highest in almost two weeks, after the Energy Information Administration reported a 1.2 million-barrel weekly rise...
: Reata’s new rare-disease drug will cost $370,000 per year
Reata Pharmaceuticals Inc.’s RETA newly approved treatment for Friedreich’s ataxia will have a wholesale acquisition price of $370,000 per year, the company told investors on...